Latest Content

AI is reshaping psychopharmacology—from TRD prediction to digital phenotyping—while exposing data limits, workflow hurdles, and safety risks in suicide tools.

Experts explain why every diagnosis needs metabolic screening, how to discuss risk safely, and when to use tools like PsyMetRiC to assess risk.

Psychiatrists unpack parental leave anxiety, FMLA gaps, and how smarter time-off planning can reduce postpartum depression and support working families.

Phase 3 data show COMP360 psilocybin delivers rapid, lasting relief in treatment-resistant depression; FDA filing advances toward 2027 launch.

Open-label phase 2 trial tests IV Briumvi alongside antipsychotics for treatment-resistant schizophrenia, targeting B-cell depletion to improve symptoms and assess safety.

Share insights on substance use care—practice tips, research, and cases—for Psychiatric Times’ July 2026 series. Pitch your article today.

ASCP panel offers deprescribing guidance to curb psychiatric overprescribing, simplify polypharmacy, and improve outcomes with tapering and

Psychiatrists debunk 10 common antidepressant myths—placebo claims, addiction fears, suicide risk, overuse, and withdrawal—offering evidence-based guidance.

In the first ever episode of "On Your Mind With Erin Crown," explore how tribalism hurts the field of psychiatry and ultimately patient outcomes.

AI may assist psychopharmacology by aiding suicide risk, digital phenotyping, and TRD care—while exposing EHR data limits and the need for smarter integration.

Track latest neuropsychiatry breakthroughs: phase 3 narcolepsy study launches, new depression and PTSD therapies advance, and FDA approvals reshape care.

Check out the pipeline updates from June!

Largest real-world analysis shows Deep TMS cuts PTSD and depression symptoms in comorbid patients; promising but not FDA-cleared yet.